Bioorthogonal CRISPR/Cas9-Drug Conjugate: A Combinatorial Nanomedicine Platform

Cited 2 time in webofscience Cited 0 time in scopus
  • Hit : 93
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorBeha, Marcel Janisko
dc.contributor.authorKim, Joo-Chanko
dc.contributor.authorIm, San Haeko
dc.contributor.authorKim, Yunsuko
dc.contributor.authorYang, Seungjuko
dc.contributor.authorLee, Juheeko
dc.contributor.authorNam, Yu Riko
dc.contributor.authorLee, Haeshinko
dc.contributor.authorPark, Hee-Sungko
dc.contributor.authorChung, Hyun Jungko
dc.date.accessioned2023-10-06T02:00:53Z-
dc.date.available2023-10-06T02:00:53Z-
dc.date.created2023-08-07-
dc.date.created2023-08-07-
dc.date.issued2023-09-
dc.identifier.citationADVANCED SCIENCE, v.10, no.27-
dc.identifier.issn2198-3844-
dc.identifier.urihttp://hdl.handle.net/10203/313060-
dc.description.abstractBioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self-delivered nanomedicine platform based on bioorthogonal CRISPR/Cas9 conjugates, which can be armed with a chemotherapeutic drug for combinatorial therapy is introduced. It is demonstrated that multi-functionalized Cas9 with a drug and polymer can form self-condensed nanocomplexes, and induce significant gene editing upon delivery while avoiding the use of a conventional carrier formulation. It is shown that the nanomedicine platform can be applied for combinatorial therapy by incorporating the anti-cancer drug olaparib and targeting the RAD52 gene, leading to significant anti-tumor effects in BRCA-mutant cancer. The current development provides a versatile nanomedicine platform for combination treatment of human diseases such as cancer.-
dc.languageEnglish-
dc.publisherWILEY-
dc.titleBioorthogonal CRISPR/Cas9-Drug Conjugate: A Combinatorial Nanomedicine Platform-
dc.typeArticle-
dc.identifier.wosid001031571000001-
dc.identifier.scopusid2-s2.0-85165483453-
dc.type.rimsART-
dc.citation.volume10-
dc.citation.issue27-
dc.citation.publicationnameADVANCED SCIENCE-
dc.identifier.doi10.1002/advs.202302253-
dc.contributor.localauthorLee, Haeshin-
dc.contributor.localauthorPark, Hee-Sung-
dc.contributor.localauthorChung, Hyun Jung-
dc.description.isOpenAccessN-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorbioorthogonal-
dc.subject.keywordAuthorcancer therapy-
dc.subject.keywordAuthorchemotherapeutic drugs-
dc.subject.keywordAuthorcombinatorial delivery-
dc.subject.keywordAuthorCRISPR-
dc.subject.keywordAuthorCas9-
dc.subject.keywordAuthorgene editing-
dc.subject.keywordAuthornanomedicines-
dc.subject.keywordAuthorunnatural amino acids-
dc.subject.keywordPlusSYNTHETIC LETHALITY-
dc.subject.keywordPlusNANOPARTICLE DELIVERY-
dc.subject.keywordPlusGUIDE RNA-
dc.subject.keywordPlusDONOR DNA-
dc.subject.keywordPlusCAS9-
dc.subject.keywordPlusCRISPR-CAS9-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusPROTEIN-
dc.subject.keywordPlusSTRATEGIES-
dc.subject.keywordPlusCANCER-
Appears in Collection
CH-Journal Papers(저널논문)BS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 2 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0